The Company is seeking approval of tirzepatide for the treatment of HFpEF and obesity and has submitted data to the FDA. Detailed results were announced from a phase 3 clinical trial evaluating the ...

For patients with obesity and prediabetes, three years of tirzepatide yields substantial and sustained weight reductio ...

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure ...

CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...

Payers and employers have tightened access to the glucagon-like peptide-1 receptor agonist class once these therapies became ...

The detailed results were published in The New England Journal of Medicine and were presented at ObesityWeek 2024.

In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial and sustained reductions in body weight in persons with obesity over a 72-week period. Here ...

which may have been influenced by the study’s 72-week primary phase design. In conclusion, the trial shows that tirzepatide therapy could lead to sustained weight loss and significantly reduce ...

Safety experts argue that the design and structure of Tesla's Cybertruck present serious safety concerns. The vehicle's angular design and stiff stainless steel exoskeleton could be a serious ...

For many patients on tirzepatide, a transformative medication used for weight loss and diabetes, the end of the drug's shortage was anything but welcome news. "I had an anxiety attack," said Maria ...

Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of tirzepatide ...

Research indicates that its unique design may allow it to act as an ... as compared to single-receptor agonists. The peptide structure of Tirzepatide includes modifications that are believed ...